Hansa Biopharma AB (publ) (HNSA) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Hansa Biopharma Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.436 All participants will be in listen-only mode. 00:00:03.436 -- 00:00:06.760 Since you need assistance, please signal a conference specialist by pressing the star 00:00:06.760 -- 00:00:08.983 key followed by zero. 00:00:08.983 -- 00:00:12.809 After today's presentation, there will be an opportunity to ask questions. 00:00:12.809 -- 00:00:17.014 To ask a question, you may press star then one on your telephone keypad, and to withdraw 00:00:17.014 -- 00:00:19.998 your question, please press star then two. 00:00:19.998 -- 00:00:23.323 Please note, today's event is being recorded. 00:00:23.323 -- 00:00:27.549 I would now like to turn the conference over to Renee Aguiar-Lucander, Chief Executive 00:00:27.549 -- 00:00:30.871 Officer. Please go ahead. 00:00:31.300 -- 00:00:36.589 Thank you. Good afternoon and good morning, everyone, and welcome to the HANSA Biopharma 00:00:36.589 -- 00:00:39.874 Conference Call to review Q2 and half-year results for 2025. 00:00:39.874 -- 00:00:41.537 I'm 00:00:41.537 -- 00:00:46.966 Renee Aguirre-Lukander, CEO for HANSA Biopharma, and joining me today is Evan Ballantyne, 00:00:46.966 -- 00:00:52.195 Chief Financial Officer, Ito Kauffman, Chief Scientific and Technology Officer, and Maria 00:00:52.195 -- 00:00:56.462 Tarnson, Chief Operating Officer and President of the US. 00:00:56.462 -- 00:00:58.857 Please turn to slide two. 00:00:58.857 -- 00:01:02.161 Please allow me to draw your attention to the fact that we will be making forward-looking 00:01:02.161 -- 00:01:07.949 statements during this presentation, and you should therefore apply appropriate caution. 00:01:07.949 -- 00:01:10.710 Please turn to slide three. 00:01:11.013 -- 00:01:16.540 So this, today we'll discuss the progress we've made in the first...